3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
37
Carcinoma, Non-Small-Cell Lung
23
Uterine Cervical Neoplasms
22
Melanoma
22
Carcinoma, Renal Cell
18
Endometrial Neoplasms
16
Colorectal Neoplasms
15
Carcinoma, Transitional Cell
15
Triple Negative Breast Neoplasms
13
Stomach Neoplasms
13
Fallopian Tube Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Carcinoma, Hepatocellular
10
Pancreatic Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Carcinoma, Merkel Cell
8
Small Cell Lung Carcinoma
7
Prostatic Neoplasms
7
Neoplasms
7
Neoplasm Metastasis
7
Lung Neoplasms
6
Esophageal Neoplasms
6
Cholangiocarcinoma
6
Urinary Bladder Neoplasms
5
Mesothelioma
5
Lymphoma
4
Carcinosarcoma
4
Vulvar Neoplasms
3
Interventions
sarcolipin
1
TP protocol
1
Positron Emission Tomography Computed Tomography
1
Nivolumab
1
Lymph Node Excision
1
Ipilimumab
1
Drug Therapy
1
Diffusion Magnetic Resonance Imaging
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Metastasis
×
Nivolumab
×
Gynecologic
×
Clear all
NCT05504642
2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2
Withdrawn